Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome (NordiPAD)

Novo Nordisk

Status: Completed

Conditions: Growth Hormone Deficiency in Children; Genetic Disorder; Turner Syndrome; Growth Hormone Disorder

Treatments: Drug: somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT01604161

GH-3910

Details and patient eligibility

About

This study is conducted in Japan. The aim of this study is to collect information about the efficacy and safety of Norditropin® (somatropin) in the long-term treatment of short stature with GHD (Growth Hormone Deficiency) where epiphysial discs are not closed and short stature with Turner Syndrome where epiphysial discs are not closed.

Enrollment: 2,016 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Growth hormone deficiency or short stature due to Turner Syndrome where the epiphyseal discs are not closed

Exclusion criteria

• Diabetic
• Patients with malignant tumors
• Women who are either pregnant or likely to be pregnant
• Known or suspected allergy to study product(s) or related products

Trial design

2,016 participants in 1 patient group

Somatropin

Treatment:

Drug: somatropin